(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 8.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Vertex Pharmaceuticals's revenue in 2025 is $11,099,700,000.On average, 10 Wall Street analysts forecast VRTX's revenue for 2025 to be $3,058,032,065,797, with the lowest VRTX revenue forecast at $3,043,560,260,324, and the highest VRTX revenue forecast at $3,070,780,762,146. On average, 10 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,371,365,721,487, with the lowest VRTX revenue forecast at $3,184,285,118,800, and the highest VRTX revenue forecast at $3,840,016,735,805.
In 2027, VRTX is forecast to generate $3,665,510,464,176 in revenue, with the lowest revenue forecast at $3,466,762,024,500 and the highest revenue forecast at $4,330,884,558,755.